Detalhe da pesquisa
1.
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.
BMC Cancer
; 24(1): 370, 2024 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38528445
2.
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.
Br J Cancer
; 129(9): 1490-1499, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37684354
3.
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
Br J Haematol
; 202(3): 498-503, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37303189
4.
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).
BMC Cancer
; 21(1): 800, 2021 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34247580
5.
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Nat Med
; 29(7): 1760-1774, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414897
6.
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
Lancet Respir Med
; 10(3): 255-266, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34922649